SpaceX's $116B Lock-Up Cliff Meets the Biggest Reg NMS Rewrite in Two Decades

On August 6, 2026 — two days after SpaceX reports its first quarterly results as a public company — approximately 911.5 million shares of SPCX become eligible for trading as the initial tranche of a staggered lock-up schedule expires. At recent prices near $107, that unlock represents roughly $116 billion in supply hitting a stock that has already fallen about 30% from its June peak.^[1][2] It is, by orders of magnitude, the largest lock-up expiry in IPO history, and it arrives in a week when the SEC’s comment period on rescinding the Regulation NMS trade-through rule is also closing. The convergence of a historic supply event and the most significant market-structure proposal in two decades makes August 2026 a stress test for equity-market plumbing — and a revealing one.

The SPCX Lock-Up Cliff

Space Exploration Technologies Corp. priced its IPO at $135 per share on June 11, 2026, offering 555,555,555 Class A shares with a 30-day underwriter option for an additional 83,333,333 shares. The underwriters exercised that option in full, bringing the total to 638,888,888 shares and raising approximately $75 billion — surpassing Saudi Aramco’s 2019 listing as the largest IPO on record.^[3][4] The implied valuation at listing was approximately $1.75 to $1.77 trillion.^[3]

The stock opened to euphoria. SPCX peaked at $225.64 on June 16, four days after debut.^[2] Then the gravity of a $1.75 trillion price tag — roughly 90 times trailing revenue on a company posting a net loss near $5 billion in 2025 — began asserting itself.^[3] By July 23, SPCX had printed an all-time low of $110.85, and by July 28 it was changing hands near $107 intraday — 52% below the June high and 20% below the IPO price.^[2]

What happens on August 6 is not a binary cliff but a pressure-release valve opening into an already-depressed tape. The 911.5 million unlocked shares include restricted stock and option shares held by employees, early venture investors, and insiders — some sitting on gains of 100x or more from their cost basis.^[3] SEC Rule 144 will still govern how affiliates (directors, officers, and 10%+ holders like Musk) can sell: a volume cap of the greater of 1% of shares outstanding or the average weekly trading volume over the prior four weeks, executed through Form 144 filings and, in practice, pre-arranged 10b5-1 plans.^[3] The founder cannot simply dump. But non-affiliate holders — employees with vested RSUs, early funds distributing to limited partners — face no such caps once the contractual lock-up lifts.

Morningstar’s analysis frames the event starkly: the lock-up expirations could unleash stock sales that dwarf the IPO itself, and as SPCX potentially enters major indices, index funds may be forced to accumulate positions in a stock that is experiencing its most volatile supply event.^[2]

Key dates for SPCX holders

The SEC’s Market-Structure Overhaul

While SPCX’s lock-up cliff dominates the near-term tape, a slower-moving but potentially more consequential story is unfolding at the SEC. On June 11, 2026 — the same day SpaceX priced its IPO — the Commission proposed rescinding Rule 611 and Rule 610(e) of Regulation NMS.^[5] Rule 611, adopted in 2005, established the trade-through prohibition: trading centers cannot execute orders at prices inferior to protected quotations displayed elsewhere. Rule 610(e) barred locked and crossed markets. Together, these rules have shaped order routing, intermarket linkage, and the competitive structure of US equity trading for two decades.

Chairman Paul Atkins framed the proposal as simplification: “After two decades of Rule 611, it is high time that the Commission review its unintended consequences that have hindered — rather than enhanced — the long-term growth of our markets.”^[5] The comment period runs 60 days from Federal Register publication on June 17, 2026, closing approximately August 17.^[6]

What rescinding the trade-through rule would mean in practice is a shift from rigid, SEC-mandated order protection to a best-execution regime where competition and market forces determine routing.^[7] Proponents argue the current rule entrenches complexity and routing friction without meaningfully improving execution quality for investors. Critics warn that removing trade-through protection could fragment liquidity and allow inferior fills, particularly in less liquid names. Skadden’s analysis notes the proposal would also reopen the door to locked and crossed markets — quotations where the best bid equals or exceeds the best offer across venues — which Rule 610(e) has suppressed since 2005.^[7]

The Reg NMS proposal is not an isolated move. It sits inside a broader 2026 SEC capital-markets modernization agenda that, in three successive weeks of July, convened a roundtable on IPO modernization (July 8), proposed an e-delivery framework for investor disclosures (July 16), and held a roundtable on preparations for 24-hour trading (July 23).^[8] None of these are final rules — they are proposals, roundtables, and reports — but the pace and thematic overlap signal a coordinated push to reduce friction and cost across the equity-market stack, from issuance through trading through disclosure delivery.

For a stock like SPCX entering its most volatile supply window, the market-structure backdrop matters in a specific way. If the trade-through rule is eventually rescinded, the fragmentation risk that concerns critics could compound the price-discovery challenges of absorbing hundreds of millions of newly unlocked shares. Conversely, if 24-hour trading moves from roundtable to reality, the overnight sessions that currently trade thin could become meaningful venues for absorbing lock-up-release supply — though that infrastructure is months or years from operational.

The August IPO Calendar: Biotechs Lead

The IPO market entering August 2026 is not a one-name show. Renaissance Capital’s week-ahead note describes a calendar that “opens with biotechs, a bank, and SpaceX earnings” — a mix that signals the post-SpaceX issuance window is still active, even as the largest listing in history continues to dominate attention.^[9]

Apnimed (APMD), a sleep-apnea drug developer, debuted on July 31, raising $192 million — well above its $150 million target — and gained 56% in first-day trading before paring gains and being halted for volatility.^[9] Attovia Therapeutics (ATTO), a clinical-stage biopharmaceutical company developing nanobody-based biologics for immune-mediated diseases, is set to list on Nasdaq on August 5 with a roughly $200 million offering.^[10] Bending Spoons (BSP), the Italian technology company that acquires and transforms digital businesses, listed on Nasdaq on July 1.^[10] Churchill Capital XIII (XIIIU), a SPAC, raised $360 million on July 31.^[10]

The biotech clustering is notable. Fifteen biopharma IPOs have priced in the US in 2026 through July, with first-day returns running high for most — a pattern that suggests risk appetite for early-stage clinical companies has recovered meaningfully from the 2022–2023 drought.^[9] Whether that appetite survives a rough SPCX August is an open question. Lock-up events at the largest recent listing do not mechanically reset sentiment for small-cap biotechs, but a risk-off turn tied to SPCX supply pressure could spill into broader new-issue demand.

What the Lock-Up Record Shows

The historical record on mega-IPO lock-up expiries is consistent if not perfectly predictive. The pattern: a supply-driven dip in the weeks before expiry as the market prices in the coming overhang, followed by selling pressure in the days after, and then a stabilization as the new float is absorbed. The magnitude of the dip depends on the quality of natural buyers stepping in versus the volume of sellers exiting.

SpaceX’s situation has several distinguishing features. First, the sheer scale — $116 billion in unlocked shares is multiples larger than any prior lock-up event. Second, the governance structure: with Musk holding 82.4% of votes on 42% of economics through 10-vote Class B shares, the public float is economically significant but governance-irrelevant, which may deter some institutional buyers from absorbing supply.^[3] Third, the staggered schedule: the August 6 tranche is the first of several, meaning the supply overhang extends into Q4 2026 rather than clearing in a single event.^[1]

The base-rate read is that SPCX’s year-one trajectory was always likely to include a significant drawdown — Meta fell roughly 50% in its first months post-IPO before compounding at 29% annually thereafter, and Aramco declined 17–26% within a few years of listing.^[3] The lock-up cliff accelerates and intensifies that drawdown phase. The question for the market is whether the underlying franchise — Starlink’s scaling recurring revenue, launch dominance, and the optionality stack around Starship and in-space infrastructure — generates enough fundamental demand to absorb the supply before the next tranche arrives.

What to Watch Next

• August 4 (after close): SpaceX’s first earnings report. Starlink subscriber additions, revenue trajectory versus the $18.7 billion 2025 base, and commentary on xAI integration costs are the items that will shape whether buyers step in ahead of the lock-up expiry or wait for the supply to clear first.

• August 6: The first lock-up tranche. Watch volume, not just price. A high-volume session that holds above the July 23 low of $110.85 would suggest absorption; a break below it on heavy selling would signal the overhang is not yet fully priced.

• ~August 17: The SEC’s Reg NMS comment period closes. The volume and tenor of comments — particularly from exchanges, market makers, and institutional investors — will indicate whether the rescission has momentum toward a final rule or faces material opposition that could water it down.

• Q4 2026: Subsequent lock-up tranches and any potential index-inclusion event. If SPCX is added to major indices, passive funds will need to buy regardless of governance screens — a structural demand source that could offset some of the lock-up supply, but also one that concentrates buying in a mechanically determined window.

• IPO pipeline health: Whether the biotech-led August calendar sustains its momentum through September. A successful Attovia debut alongside a rough SPCX tape would suggest the new-issue market has decoupled from the mega-listing’s post-debut turbulence. A synchronized pullback would suggest the opposite.

The convergence of these threads — a record supply event, a market-structure rewrite, and an active issuance calendar — makes August 2026 one of the more revealing months for understanding how modern equity markets absorb stress. The SPCX lock-up is the visible test case. The Reg NMS proposal is the structural backdrop that will determine how future stress events route, price, and clear.

FN2 Research provides market commentary and educational analysis, not personalized investment advice. Figures are drawn from publicly available sources cited above and were current as of August 2, 2026; some data points are reported in slightly different forms across sources, and ranges are flagged where they conflict.